Analysis of Drug Safety Warnings by Global Regulators

Importance of Drug Safety in Canada

A recent study published in JAMA Internal Medicine examined the consistency of drug safety warnings among the world’s leading drug regulators. Health products, including pharmaceutical and natural health products, are vital to Canada’s healthcare system. Currently, over 22,000 human drug products are available on the Canadian market. Health Canada plays a crucial role in ensuring that these products are both safe and effective for use.

Role of Health Canada in Drug Safety

As a federal regulatory body, Health Canada collaborates with national regulatory authorities, pharmaceutical companies, healthcare professionals, and patients to balance public safety with potential risks. In 2017, Health Canada approved 67 new drugs, providing Canadians with innovative options to enhance their health. However, the information available regarding rare serious side effects, long-term effects, and outcomes for vulnerable populations is often limited when new drugs are marketed. Therefore, a timely and consistent response to drug safety alerts is essential to inform the public about new evidence of potential harm and preventive measures.

Findings on Regulatory Warning Consistency

Study Overview

The JAMA Internal Medicine study involved researchers from Australia and Canada analyzing the consistency of drug safety warnings issued by major pharmaceutical regulators in the United States (US), Canada, the United Kingdom (UK), and Australia. The analysis included 1,441 safety advisories covering 680 drug-risk issues from the US Food and Drug Administration (FDA), Health Canada, the UK Medicines and Healthcare Products Regulatory Agency, and Australia’s Therapeutic Goods Administration from 2007 to 2016.

Key Findings

The study revealed a surprising lack of concordance, with only 10% agreement among these regulators regarding warnings to physicians and the public about risks associated with approved prescription drugs. Health Canada issued advisories for only half of the drug-risk issues, which is comparable to the US FDA. In contrast, Australia’s regulator issued the fewest warnings, addressing only 70.4% of the issues, while the UK did not issue warnings for about 47% of the cases.

Need for Improved Drug Safety Communication

Impact of Adverse Drug Reactions

Adverse drug reactions are estimated to account for up to two-thirds of drug-related hospital admissions and emergency department visits, costing the Government of Canada nearly 36 million dollars, with over 80% of these costs arising from hospitalizations.

Conclusion

This study underscores the necessity for improved consistency in the communication of important drug safety notices. Further research is needed to identify the most effective methods for conveying safety warnings about drugs to better protect public health.

Written by Man-tik Choy, Ph.D.

Reference: Perry L.T. et al. Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. JAMA Internal Medicine, 2019, doi:10.1001/jamainternmed.2019.0294.